Recent Analysts’ Ratings Changes for Sanuwave Health (SNWV)

Sanuwave Health (NASDAQ: SNWV) has recently received a number of price target changes and ratings updates:

• 3/30/2026 – Sanuwave Health was downgraded by Zacks Research from “hold” to “strong sell”.
• 3/30/2026 – Sanuwave Health had its “buy” rating reaffirmed by Roth Mkm. They now have a $47.00 price target on the stock, down from $53.00.
• 3/28/2026 – Sanuwave Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/27/2026 – Sanuwave Health was upgraded by Weiss Ratings from “sell (d-)” to “hold (c-)”.

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.